Rich Pharmaceuticals's competitors

Rich Pharmaceuticals's competitors include Epizyme, Rexahn Pharmaceuticals, PDL BioPharma and GTx
Add company...
Rich Pharmaceuticals
Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, RP-323, for the treatment of acute myelogenous leukemia in refractory patients.
Epizyme
Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.
PDL BioPharma
PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities.
GTx
GTx, Inc is a pharmaceutical company and developer of drugs that utilize hormonal pathways.
Founding Date
Founding Date
N/A
Founding Date
2007
Founding Date
2001
Founding Date
1986
Founding Date
1997
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Beverly Hills, US HQ
Locations
Cambridge, US HQ
Locations
Rockville, US HQ
Locations
Incline Village, US HQ
Locations
Memphis, US HQ
Employees
Employees
1
Employees
112
Employees
20
Employees
11
Employees
26 10% decrease
Valuation ($)
Valuation ($)
206.6 k
Valuation ($)
1.1 b
Valuation ($)
50.7 m
Valuation ($)
376.2 m
Valuation ($)
249.1 m

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$8m (FY, 2016)
Revenue (est.)
N/A
Revenue (est.)
$244.3m (FY, 2016)
Revenue (est.)
N/A
Net income
Net income
N/A
Net income
($110.2m) (FY, 2016)
Net income
($9.3m) (FY, 2016)
Net income
N/A
Net income
($6.9m) (FY, 2016)
For sources of this data, please see the company profileDownload Excel

View company profiles